Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Eculizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Soliris

    02 7Soliris

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Alexion

    Eculizumab

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 4,064

    2019 Revenue in Millions : 3,946

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed

    AstraZeneca

    Eculizumab

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 1,874

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed

    AstraZeneca

    Eculizumab

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 3,762

    2021 Revenue in Millions : 1,874

    Growth (%) : 101

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    United Kingdom
    arrow
    Antibody Engineering
    Not Confirmed

    AstraZeneca

    Eculizumab

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 3,145

    2022 Revenue in Millions : 3,762

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Alexion Pharmaceuticals

    Eculizumab

    Main Therapeutic Indication : Blood Related Disorders

    Currency : USD

    2015 Revenue in Millions : 2,234

    2014 Revenue in Millions : 2,590

    Growth (%) : 16%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Alexion

    Eculizumab

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2018 Revenue in Millions : 3,563

    2017 Revenue in Millions : 3,144

    Growth (%) : 13%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Alexion

    Eculizumab

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2016 Revenue in Millions : 2,843

    2015 Revenue in Millions : 2,591

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Alexion

    Eculizumab

    Main Therapeutic Indication : Hematology

    Currency : USD

    2019 Revenue in Millions : 3,946

    2018 Revenue in Millions : 3,563

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Soliris

    Eculizumab

    arrow
    Antibody Engineering
    Not Confirmed

    Brand Name : Soliris

    U.S.A
    arrow
    Antibody Engineering
    Not Confirmed

    Alexion

    Eculizumab

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2017 Revenue in Millions : 3,144

    2016 Revenue in Millions : 2,843

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF